利福喷丁联合或不联合莫西沙星治疗人类免疫缺陷病毒感染者肺结核(S31/A5349)
结核试验联盟研究31/AIDS临床试验组A5349是一项国际随机开放标签3期非劣效性试验,在HIV感染者(CD4+≥100个/μL、接受或即将开始依非韦伦为基础抗逆转录病毒治疗)中比较4个月每日利福喷丁+莫西沙星方案与6个月标准方案。结果显示利福喷丁-莫西沙星方案非劣效于对照(不利结局绝对差异-7.4%,95%CI -20.8%至6.0%),利福喷丁方案未达非劣效(+7.5%,95%CI -7.3%至+22.4%),利福喷丁方案不良事件少于对照(15% vs 21%)。
要点
- 在HIV相关药物敏感肺结核且CD4+≥100个/μL者中,4个月利福喷丁-莫西沙星方案非劣效于6个月对照方案。
- 利福喷丁方案(不联合莫西沙星)未达非劣效于对照方案。
- 利福喷丁为基础方案的不良事件报告率(15%)低于对照方案(21%)。
核心结论
- 在HIV相关药物敏感肺结核且CD4+计数≥100个/μL、接受依非韦伦为基础抗逆转录病毒治疗者中,4个月每日利福喷丁-莫西沙星方案非劣效于6个月对照方案且安全。
研究设计与样本
- 国际随机开放标签3期非劣效性试验,纳入13个国家2516名参与者。
- HIV感染者按CD4+计数≥100个/μL且正在接受或即将开始依非韦伦为基础抗逆转录病毒治疗的条件入组。
- 随机化按研究中心、肺部空洞和HIV状态分层,HIV感染者分阶段入组以支持对利福喷丁与依非韦伦药物相互作用的谨慎评估。
- 主要终点为随机化后12个月无结核病生存(有效性)和治疗期间≥3级不良事件(安全性),有效性非劣效界值为6.6%。
主要发现
- 194名(8%)微生物学合格HIV感染者中,中位CD4+计数为344个/μL(四分位距223-455)。
- 利福喷丁-莫西沙星方案非劣效于对照:不利结局绝对差异-7.4%(95%CI -20.8%至6.0%)。
- 利福喷丁方案未达非劣效于对照:不利结局绝对差异+7.5%(95%CI -7.3%至+22.4%)。
- 利福喷丁为基础方案报告的不良事件(15%)少于对照方案(21%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) Trials Consortium Study 31/AIDS Clinical Trials Group A5349, an international randomized open-label phase 3 noninferiority trial showed that a 4-month daily regimen substituting rifapentine for rifampin and moxifloxacin for ethambutol had noninferior efficacy and was safe for the treatment of drug-susceptible pulmonary TB (DS-PTB) compared with the standard 6-month regimen. We explored results among the prespecified subgroup of people with human immunodeficiency virus (HIV) (PWH). METHODS: PWH and CD4+ counts ≥100 cells/μL were eligible if they were receiving or about to initiate efavirenz-based antiretroviral therapy (ART). Primary endpoints of TB disease-free survival 12 months after randomization (efficacy) and ≥ grade 3 adverse events (AEs) on treatment (safety) were compared, using a 6.6% noninferiority margin for efficacy. Randomization was stratified by site, pulmonary cavitation, and HIV status. PWH were enrolled in a staged fashion to support cautious evaluation of drug-drug interactions between rifapentine and efavirenz. RESULTS: A total of 2516 participants from 13 countries in sub-Saharan Africa, Asia, and the Americas were enrolled. Among 194 (8%) microbiologically eligible PWH, the median CD4+ count was 344 cells/μL (interquartile range: 223-455). The rifapentine-moxifloxacin regimen was noninferior to control (absolute difference in unfavorable outcomes -7.4%; 95% confidence interval [CI] -20.8% to 6.0%); the rifapentine regimen was not noninferior to control (+7.5% [95% CI, -7.3% to +22.4%]). Fewer AEs were reported in rifapentine-based regimens (15%) than the control regimen (21%). CONCLUSIONS: In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to the 6-month control regimen and was safe. CLINICAL TRIALS REGISTRATION: NCT02410772.
引用
- Pettit AC, Phillips PPJ, Kurbatova E, et al. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023. PMID: 36041016. doi:10.1093/cid/ciac707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。